Pharmaceutical Executive Digital Edition - February 2011

The Promise Of Translational Medicine

External Link - article-820595.pdf

Articles in this issue

over 15 years ago

Article

Skipping the Needle: Pharm Exec's Brand of the Year

over 15 years ago

Article

Honing Reforms from Clinical Development

over 15 years ago

Article

Growing Stronger After the Storm

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

ByKrista Pinto

June 29th 2026

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

ByMike Hollan

June 26th 2026

The New Healthy Aging Imperative and What It Means for Pharma

ByKirsten Whipple

June 26th 2026

Jessica Dunne, US Medical, Autoimmune Diabetes Medical Director at Sanofi

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

ByJessica Dunne

June 26th 2026

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

ByMike Hollan

June 25th 2026

Pharmaceutical Executive Digital Edition - February 2011

Articles in this issue

Related Content

Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Trending on PharmExec

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer